Juliet Preston is a freelance writer based in San Diego.
FDA Commissioner Scott Gottlieb reinforced his ‘cool new step-dad’ persona on Monday, unveiling a streamlined path for companies looking to market certain direct-to-consumer genetic tests.
Red and blue states alike are ushering in new drug price legislation, building momentum while the federal government sits on its hands. What is the likely impact of these efforts on the industry?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Gene editing offers near-limitless medical potential. The challenge is putting it into medical practice. So how is gene editing progressing, in terms of biotech pipelines, investment, and therapeutic approvals?
Remember to sleep, move, eat well, be mindful… the list goes on. With so many diverse corporate wellness initiatives, how can companies protect employees from getting overwhelmed?
As president and CEO of Rady Children’s Institute for Genomic Medicine, Dr. Stephen Kingsmore aims to set a new standard of care and patient engagement by rapid genomic sequencing to diagnose ill newborn babies.
Between 2006 and 2016, the total number of registered clinical trials increased by 650 percent. To successfully recruit and run all of those studies today, something needs to change.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
There's Amazon Fresh, Amazon Video, Amazon Web Services, and much, much more. Is it just a matter of time then, before the e-commerce giant begins selling prescription drugs? A new 30-page report by Goldman Sachs suggests the potential is definitely there.
Billion-dollar private venture capital rounds are apparently now a "thing." Roivant sealed the deal on Wednesday, following a multi-year trend towards bigger investment rounds in the life sciences.
Companies that target the microbiome for various therapies have rallied $840 million since 2010, according to a new report by Silicon Valley Bank that analyzes the wider progress of the field.
With a new take on an old skin graft approach, PolarityTE aims to capture the diversity of the tissue ecosystem, with epidermal, dermal, and hypodermal cells, fibroblasts, hair follicles — even the structural organization and blood vessel integration seen in the natural skin.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
After a drawn out week of deliberations, the now infamous "Pharma bro" Martin Shkreli has been found guilty on three out of eight counts heard in a Brooklyn Court.
Illumina spin-out Grail revealed Wednesday that Jeff Huber is stepping down as CEO of the billion-dollar early cancer detection startup.
The paternalistic worldview of the "doctor knows best" is (largely) on the way out. But what if it's replaced by data? Could data one day silence the intangible reasons patients have for requesting different therapies; or be used to deny certain therapies based on a set of probabilities?
Santa Monica, California-based Kite Pharma has jumped the Atlantic to file the first Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for a CAR-T therapy.
On Wednesday, the same day McCain's brain cancer diagnosis was publicly revealed, a paper was published in the journal Science Translational Medicine discussing a CAR-T approach to treating glioblastoma.